Cargando…
A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug
BACKGROUND: Elevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated that lipid lowering was associated with lower mortality in patients with CHD...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318928/ https://www.ncbi.nlm.nih.gov/pubmed/30606120 http://dx.doi.org/10.1186/s12872-018-0965-3 |
_version_ | 1783384973664845824 |
---|---|
author | Bogari, Neda M. Aljohani, Ashwag Amin, Amr A. Al-Allaf, Faisal A. Dannoun, Anas Taher, Mohiuddin M. Elsayed, Atalla Rednah, Dareen ibrahim Elkhatee, Osama Porqueddu, Massimo Alamanni, Francesco Khogeer, Soud Abdulraof A. Fawzy, Ahmed |
author_facet | Bogari, Neda M. Aljohani, Ashwag Amin, Amr A. Al-Allaf, Faisal A. Dannoun, Anas Taher, Mohiuddin M. Elsayed, Atalla Rednah, Dareen ibrahim Elkhatee, Osama Porqueddu, Massimo Alamanni, Francesco Khogeer, Soud Abdulraof A. Fawzy, Ahmed |
author_sort | Bogari, Neda M. |
collection | PubMed |
description | BACKGROUND: Elevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated that lipid lowering was associated with lower mortality in patients with CHD. The present study therefore aimed to investigate the consequences of the genetic variant c.553G > T (rs2075291) in apolipoprotein A5 gene to determination of triglycerides levels in CAD patients receiving, atorvastatin, lipid lowering drug. METHODS: We here report that a recently identified genetic variant, c.553G > T in the APOA5 gene which causes a substitution of a cysteine for a glycine residue at amino acid residue 185(G185C) is also associated with increased TG levels. To investigate theses effects, a case-control study compressing 608 subjects from the same area was performed. RESULTS: TG levels in T allele patients were significantly lower than the control GT allele patient (χ(2) = 2.382E2(a), P-value < 0.001). Overall, patients carrying T allele showed lower levels of TG than patients carrying GG allele. The homozygous patient for the T allele presented normal cholesterol levels of 134 mg/dl, and the levels in GG patients ranged from 25 to 340 mg/dl (P-value < 0.001). In summary, we demonstrated that the presence of c.553G > T variant (rs2075291); in APOA5 gene increases human plasma TG levels. CONCLUSION: Nevertheless, T allele is found to reduce TG levels in CAD patients who are on the cholesterol medication, atorvastatin. Thus, c.553G > T variant can be considered as a significant predicator of hypertriglyceridemia. In addition, it could be used as a hallmark for the diagnosis and prognosis of CAD. |
format | Online Article Text |
id | pubmed-6318928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63189282019-01-08 A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug Bogari, Neda M. Aljohani, Ashwag Amin, Amr A. Al-Allaf, Faisal A. Dannoun, Anas Taher, Mohiuddin M. Elsayed, Atalla Rednah, Dareen ibrahim Elkhatee, Osama Porqueddu, Massimo Alamanni, Francesco Khogeer, Soud Abdulraof A. Fawzy, Ahmed BMC Cardiovasc Disord Research Article BACKGROUND: Elevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated that lipid lowering was associated with lower mortality in patients with CHD. The present study therefore aimed to investigate the consequences of the genetic variant c.553G > T (rs2075291) in apolipoprotein A5 gene to determination of triglycerides levels in CAD patients receiving, atorvastatin, lipid lowering drug. METHODS: We here report that a recently identified genetic variant, c.553G > T in the APOA5 gene which causes a substitution of a cysteine for a glycine residue at amino acid residue 185(G185C) is also associated with increased TG levels. To investigate theses effects, a case-control study compressing 608 subjects from the same area was performed. RESULTS: TG levels in T allele patients were significantly lower than the control GT allele patient (χ(2) = 2.382E2(a), P-value < 0.001). Overall, patients carrying T allele showed lower levels of TG than patients carrying GG allele. The homozygous patient for the T allele presented normal cholesterol levels of 134 mg/dl, and the levels in GG patients ranged from 25 to 340 mg/dl (P-value < 0.001). In summary, we demonstrated that the presence of c.553G > T variant (rs2075291); in APOA5 gene increases human plasma TG levels. CONCLUSION: Nevertheless, T allele is found to reduce TG levels in CAD patients who are on the cholesterol medication, atorvastatin. Thus, c.553G > T variant can be considered as a significant predicator of hypertriglyceridemia. In addition, it could be used as a hallmark for the diagnosis and prognosis of CAD. BioMed Central 2019-01-03 /pmc/articles/PMC6318928/ /pubmed/30606120 http://dx.doi.org/10.1186/s12872-018-0965-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Bogari, Neda M. Aljohani, Ashwag Amin, Amr A. Al-Allaf, Faisal A. Dannoun, Anas Taher, Mohiuddin M. Elsayed, Atalla Rednah, Dareen ibrahim Elkhatee, Osama Porqueddu, Massimo Alamanni, Francesco Khogeer, Soud Abdulraof A. Fawzy, Ahmed A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug |
title | A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug |
title_full | A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug |
title_fullStr | A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug |
title_full_unstemmed | A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug |
title_short | A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug |
title_sort | genetic variant c.553g > t (rs2075291) in the apolipoprotein a5 gene is associated with altered triglycerides levels in coronary artery disease (cad) patients with lipid lowering drug |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318928/ https://www.ncbi.nlm.nih.gov/pubmed/30606120 http://dx.doi.org/10.1186/s12872-018-0965-3 |
work_keys_str_mv | AT bogarinedam ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT aljohaniashwag ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT aminamra ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT alallaffaisala ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT dannounanas ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT tahermohiuddinm ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT elsayedatalla ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT rednahdareenibrahim ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT elkhateeosama ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT porqueddumassimo ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT alamannifrancesco ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT khogeersoudabdulraofa ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT fawzyahmed ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT bogarinedam geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT aljohaniashwag geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT aminamra geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT alallaffaisala geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT dannounanas geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT tahermohiuddinm geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT elsayedatalla geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT rednahdareenibrahim geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT elkhateeosama geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT porqueddumassimo geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT alamannifrancesco geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT khogeersoudabdulraofa geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug AT fawzyahmed geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug |